Chardan Capital disclosed Alnylam Pharma (NASDAQ:ALNY), hiking its price target to $89.00 earlier today
- Updated: November 29, 2016
Having a price of $46.03, Alnylam Pharma (NASDAQ:ALNY) traded 1.59% higher on the day. With the last close down -23.05% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the same period. ALNY has recorded a 50-day average of $40.00 and a two hundred day average of $59.82. Trade Volume was down over the average, with 20 shares of ALNY changing hands under the typical 1,486,620
Reporting a potential upside of 0.93%, Chardan Capital upped the price target of Alnylam Pharma (NASDAQ:ALNY) to $89.00
On 11/16/2016, Needham released a statement on Alnylam Pharma (NASDAQ:ALNY) dropped the target price from $137.00 to $98.00 that suggested an upside of 1.03%.
Recent Performance Chart
Alnylam Pharma has with a one year low of $31.38 and a one year high of $109.10 and has a market capitalization of $0.
A total of 11 analysts have released a report on Alnylam Pharma. Three analysts rating the company a strong buy, eight analysts rating the company a buy, two analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $117.09.
General Company Details For Alnylam Pharma (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases. Its Genetic medicines include Patisiran (ALN-TTR02) and Fitusiran (ALN-AT3), and additional genetic programs, including ALN-AAT.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.